Publications

2018

Efficacy of milciclib (PHA-848125AC), a pan-cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients.
Benjamin Besse, Marina Chiara Garassino, Arun Rajan, Silvia Novello, Julien Mazieres, Glen J. Weiss, Darren Kocs, Mark Barnett, Cristina Davite, Patrizia Crivori, Giuseppe Giaccone
J Clin Oncol 36, 2018 (suppl; abstr 8519)
2018 ASCO Annual Meeting - Abstr N. 8519

2017

Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors
Glen J. Weiss1*, Gayle Jameson1, Daniel D. Von Hoff1, Barbara Valsasina, Cristina Davite, Claudia Di Giulio, Francesco Fiorentini, Rachele Alzani, Patrizia Carpinelli, Alessandro DiSanzo, Arturo Galvani, Antonella Isacchi, and Ramesh K. Ramanathan1.
Invest New Drugs. 2018 Feb; 36(1): 85-95. Epub 2017 Jul 20

2016

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
Andrea Sartore-Bianchi; Elena Ardini; Roberta Bosotti; Alessio Amatu; Emanuele Valtorta; Alessio Somaschini; Laura Raddrizzani; Laura Palmeri; Patrizia Banfi; Erica Bonazzina; Sandra Misale; Giovanna Marrapese; Antonella Leone; Rachele Alzani; David Luo; Zachary Hornby; Jonathan Lim; Silvio Veronese; Angelo Vanzulli; Alberto Bardelli; Marcella Martignoni; Cristina Davite; Arturo Galvani; Antonella Isacchi; Salvatore Siena
JNCI J Natl Cancer Inst (2016) 108(1): djv306

Capecitabine with/without mtomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma
Cereda, S., Milella, M., Cordio, S., Leone, F., Aprile, G., Galiano, A., Mosconi, S., Vasile, E., Santini, D., Belli C., Auriemma, A., Novarino, A., Vaccaro, V., Martines, C., Marino, D., Lutrino, S.E., Palazzo, V., Reinach, B., Aldrighetti, L., Reni, M.
Cancer Chemother Pharmacol, 77, 109-114

Late relapses, up to 45 months after imatinib discontinuation: results from the ISAV study
Silvia Mori, Philippe le Coutre, Elisabetta Abruzzese, Bruno Martino, Ester Pungolino, Chiara Elena, Micaela Bergamaschi, Sarit Assouline, Eros DiBona, Antonella Gozzini, Macio Andrade, Fabio Stagno, Alessandra Iurlo, Michela Luciani, Raffaella Tosetti, Dong-Wook Kim, Alessandra Pirola, Michela Viltadi, Maria Luisa Bonanomi, Patrizia Crivori, Rocco Piazza, Carlo Gambacorti-Passerini.
21st EHA Congress, June 2016,
Abstract P232

2015

A Phase I Study of Danusertib (PHA-739358) in Adult Patients with Accelerated or Blastic Phase Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant or Intolerant to Imatinib and/or Other 2nd Generation c-ABL Therapy.
Borthakur G, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Jabbour E, Mariani M, Capolongo L, Carpinelli P, Davite C, Kantarjian H and Cortes JE.
Haematologica, 100(7)

Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study
Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E, Elena C, Pierri I, Assouline SE, D'Emilio A, Gozzini A, Giraldo P, Stagno F, Iurlo A, Luciani M, De Riso G, Redaelli S, Dong-Wook K, Pirola A, Mezzatesta C, Petroccione A, Lodolo D'Oria A, Crivori P, Piazza R and Gambacorti-Passerini C
American Journal of Hematology (AJH), Vol. 90, No. 10, October 2015,910-914.

Efficacy and safety of biweekly intravenous administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small cell and non-small cell lung cancer: a multi-tumour, multi-institutional Phase II study
Schöffski P, Besse B, Gauler T, de Jonge MJA, Scambia G, Santoro A, Davite C, Jannuzzo MG, Petroccione A, Delord JP
Ann Oncol, 26(3): 598-607

Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months
Silvia Mori, PhD, Philipp le Coutre, MD, Elisabetta Abruzzese, MD, Bruno Martino, MD, Ester Pungolino, MD, Chiara Elena, MD, Ivana Pierri, MD, Sarit E. Assouline, MD MSc, Anna D'Emilio, MD, Antonella Gozzini, MD, Pilar Giraldo, MD, PhD, Fabio Stagno, MD, PhD, Alessandra Iurlo, MD, PhD, Andrea Aroldi, MD, Michela Luciani, RN, Giulia De Riso, RN, Kim Dong-Wook, MD, PhD, Alessandra Pirola, MSc, Anna Petroccione, Maria Luisa Bonanomi, Patrizia Crivori, PhD, Rocco Piazza, MD, PhD and Carlo Gambacorti-Passerini, MD
57th ASH Annual Meeting, December 2015
Blood 2015 126(23): 2775

Abstract P2775

Phase II study of Temozolomide (TMZ) in metastatic colorectal cancer (mCRC) patients molecularly selected by MGMT promoter hypermethylation
Alessio Amatu, Katia Bencardino, Ludovic Barault, Andrea Cassingena, Erica Bonazzina, Silvia Ghezzi, Catia Moutinho, Federica Tosi, Riccardo Ricotta, Elena Magni, Rosalinda Gatto, Giovanna Marrapese, Manel Esteller, Alberto Bardelli, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Salvatore Siena.
50th ASCO Annual Meeting - Gastrointestinal Cancers Symposium January 2015. J Clin Oncol. ,33: 3 suppl
Abstract 583

2014

A Phase II Multi-Center Trial Of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) In Older Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients
Marco Montillo, Davide Rossi, Marina Motta, Giulia Quaresmini, Marianna Rossi, Marta Coscia, Antonella Anastasia, Fausto Rossini, Agostino Cortellezzi, Guido Nador, Lydia Scarfò, Roberto Cairoli, Anna Maria Frustaci, Daniela Dal Ceggio, Paola Picardi, Lorenzo De Paoli, Ester Orlandi, Alessandro Rambaldi, Enrica Morra, Massimo Massaia, Alessandra Tedeschi
20th Congress of EHA, June 2014
Abstract P249

A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC).
Besse B., Garassino M.C, Rajan A., Novello S., Mazieres J., Weiss G.J., Ciomei M., Martignoni M., Petroccione A., Davite C., Giaccone G.
Proceedings of Annual Meeting Am. Soc. Clin. Oncol. 2014, J Clin Oncol , 32: 5 supll
Abstract 7526

Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial.
Giannatempo P, Nicolai N, Farè E, Raggi D, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Crestani A, Togliardi E, Salvioni R, Gianni A M, Necchi N.
49th ASCO Annual Meeting - Genitourinary Cancers Symposium, May 2014.
J Clin Oncol., 32: 4 suppl

Abstract 376

Age and Digital PCR Analysis Predict Relapses OF CML Patients Following Programmed Imatinib Interruption In Q-RT-PCR Negative Chronic Myeloid Leukemia Patients
Silvia Mori, Elisabetta Vagge, Philipp le Coutre, Elisabetta Abruzzese, Bruno Martino, Ester Pungolino, Chiara Elena, Ivana Pierri, Sarit Assouline, Anna d'Emilio, Antonella Gozzini, Pilar Gilardo, Fabio Stagno, Alessandra iurlo, Christian Rizzo,Alessia Fossat, Dong-Wook Kim, Alessandra Pirola, Anna Petroccione, Agnese Lodolo D'Oria, Patrizia Crivori, Rocco Piazza and Carlo Gambacorti Passerini
19th Congress of EHA, June 2013,EHA online
Abstract P283

Capecitabine (C) or Capecitabine plus Mitomycin C (M): results of a randomised phase II trial of second line therapy in advanced biliary tract adenocarcinoma (BTA)
Cereda S, Milella M, Cordio S, Leone F, Aprile G, Lonardi S, Mosconi S, Vasile E, Santini D, Belli C , Tortora G, Novarino A, Palazzo V, Reinach B, Reni M
XVI Congresso Nazionale AIOM, 24-26 ottobre 2014
Abstract B10

Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey.
Grosso, G., Rossetti, D., Coccolini, F., Bogani, G., Ansaloni, L., & Frigerio, L.
Archives of gynecology and obstetrics, 1-10
Abstract

Lo studio multicentrico ROL “Confronto risultati clinici e caratteristiche biomolecolari nei carcinomi colon retto screen vs non screen detected vs intervallari”, nel contesto dei programmi di screening di Regione Lombardia
Bruno Andreoni, Cristiano Crosta, Romano Sassatelli, Emanuela Anghinoni, Carlo Senore, Manuel Zorzi, Danilo Cereda, Filippo Crivelli, Angelica Sonzogni, Paola Naggi, Luca Ansaloni, Roberto Biffi, Antonio Chiappa
116° Congresso Nazionale della Società Italiana di Chirurgia, 12-15 ottobre 2014
Abstract

The Risk of Relapse in CML Patients Who Discontinued Imatinib Can Be Predicted Based on Patients Age and the Resulta of dPCR Analysis
Silvia Mori, Elisabetta Vagge, Philipp le Coutre, Elisabetta Abruzzese, Bruno Martino, Ester Pungolino, Chiara Elena, Ivana Pierri, Sarit Assouline, Anna d'Emilio, Antonella Gozzini, Pilar Gilardo, Fabio Stagno, Alessandra iurlo, Michela Luciani, Giulia De Riso, Dong-Wook Kim, Alessandra Pirola, Anna Petroccione, Agnese Lodolo D'Oria, Patrizia Crivori, Rocco Piazza and Carlo Gambacorti Passerini
56th ASH Annual Meeting, December 2014
Abstract 813 (Oral presentation)

2013

A Phase II Multi-Center Trial Of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) In Older Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients
Marco Montillo, Davide Rossi, Marina Motta, Giulia Quaresmini, Marianna Rossi, Marta Coscia, Antonella Anastasia, Fausto Rossini, Agostino Cortelezzi, Guido Nador, Lydia Scarfò, Roberto Cairoli, Daniela Dal Ceggio, Lorenzo De Paoli, Enrica Morra, Alessandro Rambaldi, Ester Orlandi, Massimo Massaia and Alessandra Tedeschi
55th ASH Annual Meeting, December 2013 - Blood, 122 (21)
Abstract 4177

Peritoneal carcinomatosis.
Coccolini, F., Gheza, F., Lotti, M., Virzì, S., Iusco, D., Ghermandi, C., Melotti R, Baiocchi G, Giulini SM, Ansaloni L, Catena F
World journal of gastroenterology, 19(41), 6979.

Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC)
Gauler TC, Besse B, Novello S, Smit EG,Plummer ER, Delord JP, Nicodemo M, Santoro A, Barone C, Marchetti P, Conte PF, De Jonge MJ, Awada A, Mariani M, Jannuzzo MG, Petroccione A, Ceruti R, Davite C, Eberhardt WEE.
Proceedings of Annual Meeting Am. Soc. Clin. Oncol. 2013, J Clin Oncol,31:15 suppl
Abstract e19138

Phase II trial of nemorubicin hydrochloride (N) in combination with cisplatin (cDDP) administered by intra-hepatic artery (IHA) in patients (pts) with hepatocellular carcinoma (HCC): Final results.
Izzo F., Vogl T. J., Gadaleta-Caldarola G., Middleton M. R. , Valle J. W. , Hammerstingl R., Gadaleta C. D., Martignoni M., Petroccione A., Mariani M., Davite C., Fiore F.
Proceedings of Annual Meeting Am. Soc. Clin. Oncol. 2013, J Clin Oncol, 31\
Abstract e15061

Validation of a Digital-PCR Analysis through Programmed Imatinib Interruption in Q-RT-PCR Negative Chronic Myeloid Lekemia Patients
Silvia Mori, Elisabetta Vagge, Philipp le Coutre, Elisabetta Abruzzese, Bruno Martino, Ester Pungolino, Chiara Elena, Ivana Pierri, Sarit Assouline, Anna d'Emilio, Antonella Gozzini, Pilar Gilardo, Fabio Stagno,Arnon Nagler, Alessandra iurlo, Christian Rizzo, Alessia Fossati, Enrico Maria Pogliani, Dong-Wook Kim, Alessandra Pirola, Rocco Piazza and Carlo Gambacorti Passerini
55th ASH Annual Meeting 2013 - Blood , 122 (21)
Abstract 4040

2012

Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer
Ansaloni L1, Agnoletti V, Amadori A, Catena F, Cavaliere D, Coccolini F, De Iaco P, Di Battista M, Framarini M, Gazzotti F, Ghermandi C,Kopf B, Saponara M, Tauceri F, Vallicelli C, Verdecchia GM, Pinna AD
International Journal of Gynecological Cancer, 22(5), 778-785.

Phase I Study of the Safety, Tolerability and Pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin dependent inhibitor, ij Patients with Advanced Solid Malignacies
Weiss GJ, Hidalgo M, Borad M, Laheru D, TibesR, Ramanathan RK, Blaydorn L, Jameson G, Jimeno A, Isaacs JD, Scaburri A, Pacciarini MA, Fiorentini F, Ciomei M, Von Hoff DD.
Invest New Drugs. (Epub 2011 Dec 9),30(6): 2334-43

Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies
Glen J. Weiss, Manuel Hidalgo, Mitesh J. Borad, Daniel Laheru, Raoul Tibes, Ramesh K. Ramanathan, Lisa Blaydorn, Gayle Jameson, Antonio Jimeno, Jeffrey D. Isaacs, Angela Scaburri, Maria Adele Pacciarini, Francesco Fiorentini, Marina Ciomei, and Daniel D. Von Hoff
Invest New Drugs. Dec 2012; 30(6): 2334–2343.

Randomized phase II study of Danusertib (formerly PHA-739358) in patients with metastatic Castration Resistant Prostate Cancer (CRPC) after docetaxel failure.
Meulenbeld HJ, Bleuse JP, Vinci EM, Raymond E, Vitali G, Santoro A, Dogliotti L, Berardi R, Cappuzzo F, Tagawa ST, Sternberg CN, Jannuzzo MG, Mariani M, Petroccione A, de Wit R.
BJU Int., 111(1): 44–52

Ureteral stenting in cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy as a routine procedure: evidence and necessity.
Coccolini, F., Lotti, M., Manfredi, R., Catena, F., Vallicelli, C., De Iaco, P. A., Da Pozzo L, Frigerio L, Ansaloni, L.
Urologia internationalis, 89(3), 307-310.

2011

A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors.
Massard C, Soria JC, Anthoney DA, Proctor A, Scaburri A, Pacciarini MA, Laffranchi B, Pellizzoni C, Kroemer G, Armand JP, Balheda R, Twelves CJ.
Cell Cycle. (Epub 2011 Mar 15), 10(6): 963-70
Abstract

Randomized Phase II study of danusertib (D) in second-line metastatic castration resistant prostate cancer (CRPC)
Bleuse P, Meulenbeld HJ, Vinci EM, Raymond E, Vitali G, Santoro A, Dogliotti L, Berardi R, Cappuzzo F, Tagawa ST, Stenberg CN, Jannuzzo MG, Mariani M, Petroccione A, De Wit R.
Proceedings of Annual Meeting Am. Soc. Clin. Oncol. 2011, J Clin Oncol, 29:15 suppl
Abstract 4628

2010

Danusertib, A Pan-Aurora Kinase Inhibitor: Clinical Review
Laffranchi B, Mariani M, Zanchetta D, Reinach BAM, Zeni A, Comis S, Carpinelli P and Moll JK
TAT 2010
Abstract O43

Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
Caponigro F, Lorusso D, Fornari G, Barone C, Merlano M, Airoldi M, Schena M, MacArthur R, Weitman S, Jannuzzo MG, Crippa S, Fiorentini F, Petroccione A, Comis S.
Cancer Chemother Pharmacol, 66(2): 389-394

Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors.
Rosen P, Tolcher A, Lee P, Smitley M, Fuerst M, Spinelli R, Crippa S, Jannuzzo MG, Comis S, Papadopoulos K.
Proceedings of Annual Meeting Am. Soc. Clin. Oncol. 2010, J Clin Oncol, 28:15 suppl
Abstract 3066

Phase I study of the oral CDK-TRKA inhibitor PHA-848125 administered with prolonged schedules of administration
Cresta S. , Sessa C. , Del Conte G., Locatelli A. , Gallerani E. , Fiorentini F. , Scaburri A., Pacciarini M. A. , Alzani R. , Gianni L.
Proceedings of Annual Meeting Am. Soc. Clin. Oncol. 2010, J Clin Oncol, 28: 15 suppl
Abstract 3065,3056

Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in combination with gemcitabine in advanced solid tumors.
Bahleda R, Spreafico A, Soria J, Moldovan C, Belli C, Fiorentini F, Scaburri A, Pacciarini MA, Laffranchi B, Reni M
Proceedings of Annual Meeting Am. Soc. Clin. Oncol. 2010, J Clin Oncol, 28:15 suppl "
Abstract 3063

Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in recurrent malignant glioma (MG).
Benouaich-Amiel A, Mazza E, Massard C, Gaviani P, Fiorentini F, Scaburri A, Pacciarini MA and Calvo E.
Proceedings of Annual Meeting Am. Soc. Clin. Oncol. 2010, J Clin Oncol, 28:15 suppl
Abstract 2087

Phase II study of danusertib (D) in advanced/metastatic breast and ovarian cancers (BC, OC)
Gallerani E, Delord JP, Schöffski P, Vergote I, Trillet-Lenoir V, Maur M, Jannuzzo MG, Petroccione A, Locatelli G, Lorusso D.
Proceedings of Annual Meeting Am. Soc. Clin. Oncol. 2010, J Clin Oncol, 28:15 suppl
Abstract 5014

Phase II study of danusertib (D) in advanced/metastatic colorectal and pancreatic cancers (CRC, PC)
Laffranchi B, De Jonge MJ, Bajetta E, Hendlisz A, Giuliani R, Barone C, Endlicher E, Jannuzzo MG, Spinelli R, Santoro A.
Proceedings of Annual Meeting Am. Soc. Clin. Oncol. 2010, J Clin Oncol, 28:15 suppl
Abstract e13558

2009

Danusertib Hydrochloride (PHA-739358) a Multi-Kinase Aurora Inhibitor, Elicits Clinical Benefit in Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.
Cortes J, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Latini F, Capolongo L, Laffranchi B, Comis S.
ASH Annual Meeting, New Orleans Louisiana 2009, Blood,114:22 suppl
Abstract 864

Estrogen suppression of 8-week treatment with exemestane combined with triptorelin versus triptorelin alone.
Jannuzzo MG, di Salle E, Spinelli R, Pirotta N, Buchan P, Bello A.
Breast Cancer Res Treat, 113(3): 491-499

Phase II trial of nemorubicin hydrocloride (nemorubicin) in combination with cisplatin (cDDP) in patients (pts) with hepatocellular carcinoma (HCC): first step results
Izzo F.,Catino A. M. , Vogl T. J., Middleton M., Valle J. W. , Fiore F., Gadaleta C. D. , Pirotta R. M., Martignoni M. , Laffranchi B.
Proceedings of Annual Meeting Am. Soc. Clin. Oncol. 2009, J Clin Oncol 27: 15 suppl
Abstract 4593

2008

Nemorubicin hydrochloride (nemorubicin) in combination with cisplatin (cDDP): Phase I in patients (pts) with hepatocellular carcinoma (HCC)
Fiore F., Gadaleta C. D, Granetto C., Middleton M., Sorio R., Labianca R. , Valota O., Pirotta R. N., Battaglia R. , Izzo F.
Proceedings of Annual Meeting Am. Soc. Clin. Oncol.2008, J Clin Oncol ,26: 20 supll
Abstract 2572

PHA-739358, an pan-Aurora Kinase Inhibitor.
Paquette R, Shah N, Sawyers C, Martinelli G, Nicoll J, Chalukya M, Locatelli G, Capolongo L, Moll J,, Comis S, Laffranchi B.
Haematology Meeting Reports. 2008, New Drugs in Hematology , 2:5 suppl. pages 92-93

Phase I dose escalation study of the oral multi-CDK inhibitor PHA-848125
Tibes R, Jimeno A, Von Hoff DD, Walker R, Pacciarini MA, Scaburri A, Fiorentini F, Borad MJ, Jameson GS and Hidalgo MORS
Proceedings of Annual Meeting Am. Soc. Clin. Oncol.2008, J Clin Oncol, 26:15 suppl
Abstract 3531

Phase II exploratory study of brostallicin in patients with ovarian cancer resistant/refractory to platinum-based chemotherapy
Lorusso D, Zanaboni F, Scalone S, Ferrandina G, Secomandi R, G. Scambia G, Jannuzzo MG, Petroccione A, Comis S, Raspagliesi S.
Proceedings of Annual Meeting Am. Soc. Clin. Oncol.2008, J Clin Oncol, 26:15 suppl
Abstract 16520

2007

Nucleotide Excision Repair (NER) plays a central role in the mechanism of action of nemorubicin: silencing of XPG as a mechanism of resistance.
Sabatino MA, Geroni C, Capolongo L, Quintieri L, Marabese M, Cappella P, Galvani A, Broggini M.
AACR-NCI-EORTC 2007, Molecular Targets and Cancer Therapeutics
Abstract A169

PHA-739358, an Aurora Kinase Inhibitor, induces clinical responses in Chronic Myeloid Leucemia harboring T315I mutations of BCR-ABL.
Paquette R, Shah N, Sawyers C, Martinelli G, Nicoll J, Chalukya M, Fiocchi C, Rocchetti M, Comis S, Capolongo L, Laffranchi B.
ASH Atlanta Georgia 2007, Blood, 110:11 suppl
Abstract 1030

Phase I dose-escalation study of brostallicin in combination with cisplatin (cDDP) in patients with advanced solid tumors
Lorusso D, Fornari G, Caponigro F, Quirino M, Merlano M, Airoldi M, Schena M, Jannuzzo MG, Crippa S, Fiorentini F, Weitman S, and Scambia G.
Proceeding of ECCO 14, 2007, EJC Suppl, 5 No.4
Abstract 715

2006

Locoregional treatment of hepatocellular carcinoma: nemorubicin hydrocloride, a promising therapeutic option
Valota O, Pacciarini MA, Capolongo L, Geroni C, Pirotta RMN
World Conference on Interventional Oncology. Villa Erba, Cernobbio, Como (Italy). June 12-16

Mechanism of action of nemorubicin hydrochloride: new preclinical evidences supporting further clinical trias in combination with cisplatin Targeted Therapies in Cancer: Myth or Reality ?
Geroni C, Capolongo L, Sabatino MA, Valota O, Pacciarini MA, Albanesi C, Ballinari D, Broggini M.
First Internatinal Meeting Nerviano Medical Sciences 2006
Abstract 28

Nemorubicin is a non-conventional anthacicline suitable for locoregional treatment of heptocellular carcinima (HCC).
Geroni C, Valota O, Capolongo L, Quintieri L, Floreani L, Broggini M, Pacciarini MA.
National Congress–Italian Cancer Society (SIC) 2006.

Phase I/II trial of nemorubicin hydrochloride in combination with cisplatin is supported by new preclinical evidences of its mechanism of action
Pacciarini MA, Geroni C, Sabatino MA,Ciomei M, Valota O, Ballinari D, Capolongo L and Broggini M
Proceeding of Annual Meeting Am. Soc. Clin. Oncol. 2006, J Clin Oncol, 24: 18 suppl
Abstract 14116

2005

Evaluation of the effect of food and formation of exemestane using a population pharmacokinetic-pharmacodynamic approach.
Valle M, di Salle E, Jannuzzo MG, Spinelli R, Poggesi I, Rocchetti M, Verotta D.
Br J Clin Pharmacol, 59(3): 355-364

Nemorubicin: a third-generation anthracycline active on hepatocellular carcinoma (HCC).
Geroni C, Pacciarini MA, Capolongo L, Valota O, Fantin M, Albanesi C, Floreani M, Quintieri L.
47th Annual Meeting of the Italian Cancer Society (SIC). Abano Terme – Padova, October 2-5, 2005

2004

Efficacy of nemorubicin (MMDX) administered with iodinated oil via hepatic artery (IHA) to patients with unresectable primary hepatocellular carcinoma (HCC): phase II trial
Sun Y, Yang J, Luo P, Zhang Y, Yan Y, Sun L, Pacciarini M A, Valota O, Geroni C.
Proceedings of 16th EORTC-NCI- AACR Symposium on Molecular Target in Cancer Therapeutics. 2004. EJC, 2(8):143
Abstract 470

Estrogen suppression of 8-week treatment with exemestane combined with triptorelin versus triptorelin alone in healthy premenopausal women.
Jannuzzo MG, di Salle E, Spinelli R, Pirotta N, Massimini G, Buchan P, Bello A.
Proceedings of Annual Meeting Am. Soc. Clin. Oncol. 2004, J Clin Oncol, 22:14 suppl
Abstract 2041

The effect of varying degrees of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal volunteers.
Jannuzzo MG, Poggesi I, Spinelli R, Rocchetti M, Cicioni P, Buchan P.
Cancer Chemother Pharmacol, 53(6): 475-481

System.String[]

To give you a better browsing experience, NMS Group and Group Companies use own and third part cookies. Browsing this web site, you allow to use them, according to our privacy policy.